Research map: Exposure–Response Relationship of Dostarlimab in Primary Advanced/Recurrent Endometrial Cancer: Results From Interim Analysis 2 of Part 1 of the RUBY Trial

Back to the article

Papers in this map

  1. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer · Mansoor Raza Mirza · 2023 · 870 citations · Cited by this paper
  2. Thorough QT Study on the Effect of Therapeutic and Supratherapeutic Dosing of Givinostat in Healthy Volunteers · 2026 · Related
  3. Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer · Ramez Nassef Eskander · 2023 · 766 citations · Cited by this paper
  4. Distributed Manufacturing, Foreign Establishments, and Why the FDA's New Proposed Rule Matters to Clinical Pharmacology · 2026 · Related
  5. Immune checkpoint inhibitor–related dermatologic adverse events · Amaris N. Geisler · 2020 · 482 citations · Cited by this paper
  6. Pharmacokinetics, Bioequivalence, and Safety Evaluation of Two Voriconazole Tablets in Healthy Chinese Volunteers · 2026 · Related
  7. Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial · Shannon Neville Westin · 2023 · 374 citations · Cited by this paper
  8. Pharmacokinetics and Bioequivalence of Tamsulosin Hydrochloride Extended‐Release Capsules in Healthy Chinese Volunteers: A Randomized, Open‐Label, Crossover Study Under Fasting and Fed Conditions · 2026 · Related
  9. Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors · Maddalena Centanni · 2019 · 354 citations · Cited by this paper
  10. Pharmacokinetic Interaction Between Atorvastatin and Hybutimibe in Healthy Chinese Volunteers · 2026 · Related
  11. Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy · Shruti Agrawal · 2016 · 219 citations · Cited by this paper
  12. Single‐Dose Pharmacokinetic Assessment of TNX‐102 SL (Cyclobenzaprine HCl Sublingual Tablets): Results From Randomized, Open‐Label Studies in Healthy Volunteers · 2026 · Related
  13. Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer · Manash Shankar Chatterjee · 2016 · 173 citations · Cited by this paper
  14. From Reflection to Acceleration: Clinical Pharmacology’s 2025 Lessons and 2026 Opportunities · 2026 · Related
  15. Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin–paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial · M.A. Powell · 2024 · 127 citations · Cited by this paper
  16. Pharmacokinetic Comparability of ABP 654, a Biosimilar to Ustekinumab, Administered Either via Prefilled Syringe or Autoinjector in Healthy Adults: Results from a Randomized, Open‐Label, Parallel‐Group Study · 2026 · Related
  17. Chemotherapy and skin reactions · Gabriella Fabbrocini · 2012 · 100 citations · Cited by this paper
  18. Pharmacokinetics and Safety of VV116 in Subjects With Mild or Moderate Hepatic Impairment Compared With Healthy Controls: A Phase I, Open‐Label Study · 2026 · Related
  19. Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno‐Oncology and Beyond: Challenges, Perspectives, and Prospects · Haiqing Isaac Dai · 2020 · 83 citations · Cited by this paper
  20. A Phase 1 Bioequivalence Study to Assess the Pharmacokinetics, Safety and Tolerability of Guselkumab After a Single‐Dose Administration via Two Subcutaneous Injection Devices in Healthy Volunteers · 2026 · Related
  21. Preclinical characterization of dostarlimab, a therapeutic anti-PD-1 antibody with potent activity to enhance immune function in in vitro cellular assays and in vivo animal models · Sujatha Kumar · 2021 · 34 citations · Cited by this paper
  22. Population pharmacokinetic characteristics of cemiplimab in patients with advanced malignancies · Feng Yang · 2021 · 29 citations · Cited by this paper
  23. Population pharmacokinetics and exposure–response of anti‐programmed cell death protein‐1 monoclonal antibody dostarlimab in advanced solid tumours · Murad R. Melhem · 2022 · 29 citations · Cited by this paper
  24. Safety of dostarlimab in combination with chemotherapy in patients with primary advanced or recurrent endometrial cancer in a phase III, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY) · Annika Auranen · 2024 · 6 citations · Cited by this paper
  25. Population pharmacokinetics and exposure–response relationships of dostarlimab in primary advanced or recurrent endometrial cancer in part 1 of RUBY · Mita Kuchimanchi · 2024 · 3 citations · Cited by this paper
  26. Untitled · Cited by this paper

Source: OpenAlex (CC0)